Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

ABSTRACT Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.

Bibliographic Details

Main Authors:	Mucenic,Marcos, Brandão,Ajacio Bandeira de Melo, Marroni,Claudio Augusto, Fleck Junior,Alfeu de Medeiros, Zanotelli,Maria Lucia, Leipnitz,Ian, Meine,Mário Henrique, Kiss,Guillermo, Martini,Juliano, Schlindwein,Eduardo Soares, Costabeber,Ane Micheli, Sacco,Fernanda Karlinsky Rodrigues, Rossato,Giovana, Cantisani,Guido Pio Cracco
Format:	Digital revista
Language:	English
Published:	Instituto de Medicina Tropical de São Paulo 2019
Online Access:	http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652019005000501
Tags:	Add Tag No Tags, Be the first to tag this record!